Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.
Bin LiSteven A EschrichAnders E BerglundMelissa MitchellDavid FenstermacherHadi DanaeeHongyue DaiDaniel SullivanWilliam L TrepicchioWilliam S DaltonPublished in: JMIR research protocols (2017)
The TCC gene expression profiling database guided tissue selection that enriched for CD30 protein expression in a number of solid tumor types. Such an approach may improve screening efficiency for enrolling patients into biomarker-based clinical trials.
Keyphrases
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- genome wide
- hodgkin lymphoma
- chronic kidney disease
- phase ii
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- genome wide identification
- study protocol
- gene expression
- healthcare
- double blind
- transcription factor
- phase iii
- health insurance
- copy number
- adverse drug